

## **GMO Funds plc**

### **ADDITIONAL INFORMATION FOR INVESTORS IN Netherlands, Spain, Italy, Finland, Norway, France, Belgium, Portugal, Greece and Cyprus**

**This document provides additional information for investors in Netherlands, Spain, Italy, Finland, Norway, France, Belgium, Portugal, Greece and Cyprus relating to the investment in relevant sub-funds of GMO Funds plc (the “Company”), a variable capital investment company with registration number 351477 authorized in Ireland in the form of an umbrella fund with segregated liability between its sub-funds.**

**This document is supplemental to, forms part of and, should be read in conjunction with, the Prospectus for the Company dated 28 May 2024 as amended or supplemented from time to time (the “Prospectus”).**

Unless otherwise stated, all defined terms in this supplement shall have the same meaning as in the Prospectus.

**In accordance with Directive (EU) 2019/1160 of the European Parliament and of the Council of 20 June 2019 amending Directive 2009/65/EC and 2011/61/EU**, the Company has appointed GMO Netherlands B.V. to provide the facilities to perform the tasks detailed in Article 92(1) of Directive 2009/65/EC, as amended.

The contact details for GMO Netherlands B.V. are:

GMO Netherlands B.V.  
Gustav Mahlerplein 109-115,  
26th Floor,  
1082 MS,  
Amsterdam  
Email: [ComplianceUKEurope@gmo.com](mailto:ComplianceUKEurope@gmo.com)

Investors may contact GMO Netherlands B.V. using their local language.

In accordance with Article 93(1) of Directive 2009/65/EC, details regarding the provision of the facilities to perform the tasks referred to in Article 92(1) of the Directive are referenced below.

Requests to process subscriptions, repurchase and redemption orders and make other payments to unit-holders relating to the units of the Company in the above mentioned countries can be directed to GMO Netherlands B.V. at the following email address: [ComplianceUKEurope@gmo.com](mailto:ComplianceUKEurope@gmo.com).

Information on how orders can be made and how repurchase and redemption proceeds are paid can be found in the Prospectus or obtained from the following email address: [ComplianceUKEurope@gmo.com](mailto:ComplianceUKEurope@gmo.com).

Your request will be acknowledged and time and date stamped by [ComplianceUKEurope@gmo.com](mailto:ComplianceUKEurope@gmo.com) and will be forwarded to the Company’s Administrator. The Administrator will then contact you to process your request and all further communication regarding your request should be directed to this entity.

Procedures and arrangements referred to in Article 15 of Directive 2009/65/EC relating to the investors’ exercise of their rights can be found in the Prospectus, and complaints regarding your investment in the Company can be sent to the following email address: [ComplianceUKEurope@gmo.com](mailto:ComplianceUKEurope@gmo.com).

Pursuant to Chapter IX of Directive 2009/65/EC, copies of the Instrument of Incorporation, the Prospectus including its Supplements, the Key Information Documents, the audited annual report and, if subsequently published, the unaudited semi-annual report, as well as any further documents that may be listed under “Supply and Inspection of Documents” in the Prospectus, may be obtained free of charge from [www.gmo.com](http://www.gmo.com) or by contacting [ComplianceUKEurope@gmo.com](mailto:ComplianceUKEurope@gmo.com).

Date: 11 May 2026